The state of Arkansas, Arkansas counties, and Arkansas cities have filed a lawsuit against the opioid drug industry in the Circuit Court of Crittenden County. The unique litigation will represent 90 percent of Arkansas's population, with 72 counties and 210 cities participating. "Though other lawsuits have been filed in federal courts across the country, Arkansas is the only state that has united in this fashion," said Chris Villines, executive director of the Association of Arkansas Counties. Don Zimmerman, executive director of the Arkansas Municipal League, commented: "Arkansas's one-voice approach to this lawsuit is one that gives us a seat at the table. Neither the state or any county or city is big enough alone; this litigation approach ensures that recovered damages remain in Arkansas." Arkansas reportedly experiences over 400 fatal overdoses a year, a number that has increased nearly 300 percent since 2000 and "coincides with opioid sales quadrupling". The state ranks second in the nation for ages 12-17 in misuse of opioids (4.67%) behind Alabama, which is the only other state with a higher opioid prescribing rate than Arkansas, according to the U.S. Centers for Disease Control and Prevention. According to PRNewswire, "Arkansas, its counties, cities and taxpayers have funded the enormous societal costs of the opioid epidemic, but have had insufficient revenue to turn the tide of the epidemic". prnewswire.comARCounties.orgARML.org
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.